Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists *
Journal of Diabetology Research · 03.06.2025 · 11 (1)
DOI: 10.52338/jodr.2025.4833 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Diabetology Research, online erschienen am 03.06.2025. Verfasst von Délio Tiago Martins Malaquias und 18 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Tirzepatide (Mounjaro), a dual GLP-1 and GIP receptor agonist, has emerged as one of the most promising therapies for metabolic control in patients with obesity and type 2 diabetes mellitus (DM2). This systematic review aimed to evaluate the clinical efficacy and safety of tirzepatide, with a focus on reducing glycated hemoglobin (HbA1c), weight loss and cardiovascular impact. Five randomized clinical trials published between 2020 and 2023 were included. The results showed that tirzepatide promoted HbA1c reductions of between 1.8% and 2.4%, and body weight losses of up to 20.9%, being superior to other incretin-based therapies, such as semaglutide and liraglutide. In addition, three of the five included studies showed a reduction in cardiovascular events, especially in patients with DM2 and high CV risk. Tirzepatide showed a favorable safety profile, with predominantly gastrointestinal adverse effects and a low incidence of hypoglycemia. The weekly dosage and multifactorial effect make this drug an attractive option for integrated metabolic management. However, limitations such as high cost and lack of data in special populations should be considered. It is concluded that tirzepatide represents a relevant therapeutic advance, with the potential to change clinical guidelines in the treatment of obesity and DM2.
Zitieren
APA
Malaquias, D. T. M., Fernandes, P. K., Catarino, R. C. C., Bueno, R. G., Agria, G. B., Silva, J. C. F. D., Faria, A. A. M., Delgado, A. F. V., Vão, É. M. F. M., Carvalho, R. P., Yamashiro, G. C., Teodoro, L. B., Pereira, B. R., Vilela, G. P., Ferreira, J. D. C., Balzano, G. K. C., Tudela, R. R., Bezerra, T. A. R., & Junior, J. E. B. (2025). Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists *. Journal of Diabetology Research, 11(1). https://doi.org/10.52338/jodr.2025.4833
Vancouver
Malaquias DTM, Fernandes PK, Catarino RCC, Bueno RG, Agria GB, Silva JCFD, et al. Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists *. Journal of Diabetology Research. 2025;11(1). doi:10.52338/jodr.2025.4833
BibTeX
@article{Malaquias2025,
author = {Malaquias, Délio Tiago Martins and Fernandes, Pietra Kananovicz and Catarino, Riala Caroline Cheloni and Bueno, Rafaela Gonçalves and Agria, Giulia Bortoloni and Silva, José Carlos Ferreira da and Faria, Aghata Abreu Mendes and Delgado, Adriana F. Viana and Vão, Érica Miriam Fernandes Miranda and Carvalho, Raquel Perez and Yamashiro, Giovana Casarini and Teodoro, Luiza Benicio and Pereira, Beatriz Randone and Vilela, Guilherme Pio and Ferreira, Jaqueline de Carvalho and Balzano, Guilherme Kovacsik Carvalho and Tudela, Rubens Rodrigues and Bezerra, Thiago Augusto Rochetti and Junior, Joel Eloi Belo},
title = {Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists *},
journal = {Journal of Diabetology Research},
year = {2025},
volume = {11},
number = {1},
doi = {10.52338/jodr.2025.4833}
}
EUVIMED